Molecular Neurobiology

, 24:87

CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease

Article

Abstract

With the arrival of effective symptomatic treatments and the promise of drugs that may delay progression, we now need to identify Alzheimer’s disease (AD) at an early stage of the disease. To diagnose AD earlier and more accurately, attention has been directed toward peripheral biochemical markers. This article reviews promising potential cerebrospinal fluid (CSF) biomarkers for AD focussing on their role in clinical diagnosis. In particular, two biochemical markers, CSF total tau (t-tau) protein and the 42 amino acid form of β-amyloid (Aβ42), perform satisfactorily enough to achieve a role in the clinical diagnostic settings of patients with dementia together with the cumulative information from basic clinical work-up, genetic screening, and brain imaging. These CSF markers are particularly useful to discriminate early or incipient AD from age-associated memory impairment, depression, and some secondary dementias. In order to discriminate AD from other primary dementia disorders, however, more accurate and specific markers are needed. Preliminary evidence strongly suggests that quantification of tau phosphorylated at specific sites in CSF improves early detection, differential diagnosis, and tracking of disease progression in AD.

Index Entries

Alzheimer’s disease (AD) β-amyloid (Aβ) tau phosphorylated tau biochemical markers cerebrospinal fluid (CSF) diagnosis 

References

  1. 1.
    Mckhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34, 939–944.PubMedGoogle Scholar
  2. 2.
    Tierney M. C., Fisher R. H., Lewis A. J., et al. (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology 38, 359–364.PubMedGoogle Scholar
  3. 3.
    Jellinger K. A. (1996) Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol. 91, 219–220.PubMedCrossRefGoogle Scholar
  4. 4.
    Galasko D., Hansen L. A., Katzman R., Wiederholt W., Masliah E., Terry R., et al. (1994) Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch. Neurol. 51, 888–895.PubMedGoogle Scholar
  5. 5.
    The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. (1998) Consensus report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease.” Neurobiol. Aging 19, 109–116.CrossRefGoogle Scholar
  6. 6.
    Goedert M. (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. TINS 16, 460–465.PubMedGoogle Scholar
  7. 7.
    Vandermeeren M., Mercken M., Vanmechelen E., Six J., Van de Voorde A., Martin J. J., Cras P. (1993) Detection of τ proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828–1834.PubMedCrossRefGoogle Scholar
  8. 8.
    Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., Vanmechelen E. (1995) Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol. Chem. Neuropathol. 26, 231–245.PubMedGoogle Scholar
  9. 9.
    Vigo-Pelfrey C., Seubert P., Barbour R., Blomquist C., Lee M., Lee D., et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 45, 788–793.PubMedGoogle Scholar
  10. 10.
    Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., et al. (1999) Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 52, 1555–1562.PubMedGoogle Scholar
  11. 11.
    Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., et al. (1998) Cernrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community-based follow-up study. J. Neurol. Neurosurg. Psychiatry 64, 298–305.PubMedGoogle Scholar
  12. 12.
    Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., et al. (1998) Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer’s disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 20, 227–235.PubMedGoogle Scholar
  13. 13.
    Skoog I., Vanmechelen E., Andreasson L. A., Palmertz B., Davidsson P., Hesse C., and Blennow K. (1995) A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4, 433–442.PubMedCrossRefGoogle Scholar
  14. 14.
    Arai H., Satoh-Nakagawa T., Higuchi M., Morikawa Y., Miura M., Kawakami H., et al. (1998) No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci. Lett. 256, 174–176.PubMedCrossRefGoogle Scholar
  15. 15.
    Mecocci P., Cherubini A., Bregnocchi M., Chionne F., Cecchetti R., Lowenthal D. T., and Senin U. (1998) Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis. Assoc. Disord. 12, 211–214.PubMedCrossRefGoogle Scholar
  16. 16.
    Arai H., Higuchi S., and Sasaki H. (1997) Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer’s disease. Gerontology 43(Suppl. 1), 2–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Green A. J., Harvey R. J., Thompson E. J., and Rossor M. N. (1999) Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s disease. Neurosci. Lett. 259, 133–135.PubMedCrossRefGoogle Scholar
  18. 18.
    Molina L., Touchon J., Herpe M., Lefranc D., Duplan L., Cristol J. P., et al. (1999) Tau and apo E in CSF: potential aid for discriminating Alzheimer’s disease from other dementias. Neuroreport 10, 3491–3495.PubMedCrossRefGoogle Scholar
  19. 19.
    Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C. M., Miura M., et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Comm. 236, 262–264.PubMedCrossRefGoogle Scholar
  20. 20.
    Higuchi M., Tashiro M., Arai H., Okamura N., Hara S., Higuchi S., et al. (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp. Neurol. 162, 247–256.PubMedCrossRefGoogle Scholar
  21. 21.
    Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., et al. (1995) Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol. 38, 643–648.PubMedCrossRefGoogle Scholar
  22. 22.
    Sjögren M., Minthon L., Davidsson P., Granérus A. K., Clarberg A., Vanderstichele H., et al. (2000) CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Transm. 107, 563–579.PubMedCrossRefGoogle Scholar
  23. 23.
    Kanemaru K., Kameda N., and Yamanouchi H. (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 54, 1875–1876.PubMedGoogle Scholar
  24. 24.
    Kudo T., Mima T., Hashimoto R., Nakao K., Morihara T., Tanimukai H., et al. (2000) Tau protein is a potential biological marker for normal pressure hydrocephalus. Psych. Clin. Neurosci. 54, 199–202.CrossRefGoogle Scholar
  25. 25.
    Mitani K., Furiya Y., Uchihara T., Ishii K., Yamanouchi H., Mizusawa H., and Mori H. (1998) Increased CSF tau protein in corticobasal degeneration. J. Neurol. 245, 44–46.PubMedCrossRefGoogle Scholar
  26. 26.
    Morikawa Y., Arai H., Matsushita S., Kato M., Higuchi S., Miura M., et al. (1999) Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin. Exp. Res. 23, 575–577.PubMedGoogle Scholar
  27. 27.
    Urakami K., Mori M., Wada K., Kowa H., Takeshima T., Arai H., et al. (1999) A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci. Lett. 259, 127–129.PubMedCrossRefGoogle Scholar
  28. 28.
    Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., and Blennow K. (2000) Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischaemic stroke. J. Alzheimer Dis. 2, 199–206.Google Scholar
  29. 29.
    Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., et al. (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225, 210–212.PubMedCrossRefGoogle Scholar
  30. 30.
    Van Everbroeck B., Green A. J. E., Phals P., Martins J. J., and Cras P. (1999) Decreased levels of amyloid β 1–42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J. Alzheimer Dis. 1, 419–424.Google Scholar
  31. 31.
    Emery V. O. and Oxman T. E. (1992) Update on the dementia spectrum of depression. Am. J. Psychiatry 149, 305–317.PubMedGoogle Scholar
  32. 32.
    Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., et al. (1999) Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample. Neurology 53, 1488–1494.PubMedGoogle Scholar
  33. 33.
    Buerger nee Buch K., Padberg F., Nolde T., Teipel S. J., Stubner S., Haslinger A., et al. (1999) Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer’s disease compared with controls. Neurosci. Lett. 277, 21–24.CrossRefGoogle Scholar
  34. 34.
    Buerger K., Zinkowski R., Teipel S. J., Tapiola T., Arai H., Blennow K., et al. CSF tau protein phosphorylated arthreonine 231 in the differential diagnosis of Alzheimer’s disease. Submitted, 2001.Google Scholar
  35. 35.
    Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., and Blennow K. (2001) Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci. Lett. 297, 187–190.PubMedCrossRefGoogle Scholar
  36. 36.
    Hampel H., Buerger K., Kohnken R., Teipel S. J., Zinkowski R., Moeller H. J., et al. (2001) Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49, 545–546.PubMedCrossRefGoogle Scholar
  37. 37.
    Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., et al. (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann. Neurol. 45, 504–511.PubMedCrossRefGoogle Scholar
  38. 38.
    Andreasen N., Hesse C., Davidsson P., Wallin A., Minthon L., Winblad B., et al. (1999) Cerebrospinal fluid β-amyloid(1-42) in Alzheimer’s disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673–680.PubMedCrossRefGoogle Scholar
  39. 39.
    Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. (2001) Evaluation of CSF t-tau and CSF-Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch. Neurol. 58, 373–379.PubMedCrossRefGoogle Scholar
  40. 40.
    Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., Schroter A., Ratzka P., et al. (2000) Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54, 1099–1102.PubMedGoogle Scholar
  41. 40a.
    Sjögren M., Gisslén M., Vanmechelen E., and Blennow K. (2001) Low cerebrosinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 314, 33–36.PubMedCrossRefGoogle Scholar
  42. 41.
    Folstein M., Folstein S., and McHugh P. (1975) “Mini-Mental State” A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198.PubMedCrossRefGoogle Scholar
  43. 42.
    Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., and Kokmen E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308.PubMedCrossRefGoogle Scholar
  44. 43.
    Arai H., Nakagawa T., Kosaka Y., Higuchi M., Matsui T., Okamura N., et al. (1997) Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer’s Res. 3, 211–213.Google Scholar
  45. 44.
    Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Longitudinal studies of cerebrospinal fluid biochemistry in patients with mild cognitive impairment. Submitted, 2001.Google Scholar
  46. 45.
    Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., et al. (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166, 201–203.PubMedCrossRefGoogle Scholar
  47. 46.
    Blennow K., Wallin A., and Häger O. (1993) Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88, 221–223.PubMedCrossRefGoogle Scholar
  48. 47.
    Kosunen O., Soininen H., Paljärvi L., Heinonen O., Talasniemi S., and Riekkinen P. J., Sr. (1996) Diagnostic accuracy of Alzheimer’s disease: a neuropathological study. Acta Neuropathol. 91, 185–193.PubMedCrossRefGoogle Scholar
  49. 48.
    Tomlinson B. E. and Henderson G. (1976) Some quantitative cerebral findings in normal and emented old people, in Neurobiology of Aging (Terry R. D. and Gershon S., eds.), Raven Press, New York, NY, pp. 183–204.Google Scholar
  50. 49.
    Davies L., Wolska B., Hilbich C., et al. (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease. Neurology 38, 1688–1693.PubMedGoogle Scholar
  51. 50.
    Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann. Neurol. 45, 358–368.PubMedCrossRefGoogle Scholar
  52. 51.
    Kahle P. J., Jakowec M., Teipel S. J., Hampel H., Petzinger G. M., Di Monte D. A., et al. (2000) Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 54, 1498–1504.PubMedGoogle Scholar
  53. 52.
    Hampel H., Teipel S. J., Padberg F., Haslinger A., Riemenschneider M., Schwarz M. J., et al. (1999) Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res. 823, 104–112.PubMedCrossRefGoogle Scholar
  54. 53.
    Jensen M., Basun H., and Lannfelt L. (1995) Increased cerebrospinal fluid tau in patients with Alzheimer’s disease. Neurosci. Lett. 186, 189–191.PubMedCrossRefGoogle Scholar
  55. 54.
    Riemenschneider M., Buch K., Schmolke M., Kurz A., and Guder W. G. (1996) Cerebrospinal protein tau is elevated in early Alzheimer’s disease. Neurosci. Lett. 212, 209–211.PubMedCrossRefGoogle Scholar
  56. 55.
    Rösler N., Wichart I., and Jellinger K. A. (1996) Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 60, 237–238.PubMedGoogle Scholar
  57. 56.
    Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., et al. (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta 1-40, and A beta 1-42(43) in Alzheimer’s disease: a study in Japan. Ann. Neurol. 44, 17–26.PubMedCrossRefGoogle Scholar
  58. 57.
    Kurz A., Riemenschneider M., Buch K., Willoch F., Bartenstein P., Muller U., and Guder W. (1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12, 372–377.PubMedGoogle Scholar
  59. 58.
    Tapiola T., Lehtovirta M., Ramberg J., Helisalmi S., Linnaranta K., Riekkinen P Sr., and Soininen H. (1998) CSF tau is related to apolipoprotein E genotype in early Alzheimer’s disease. Neurology 50, 169–174.PubMedGoogle Scholar
  60. 59.
    Vanderstichele H., Blennow K., D’Heuvaert N. D., Buyse M. A., Wallin A., Andreasen N., et al. (1998) Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF in Progress in Alzheimer’s and Parkinson’s Diseases (Fisher A., Hanin I., and Yoshida M., eds.), Plenum Press, New York, NY, pp. 773–778.Google Scholar
  61. 60.
    Ishiguro K., Ohno H., Arai H., Yamaguchi H., Urakami K., Park J. M., et al. (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci. Lett. 270, 91–94.PubMedCrossRefGoogle Scholar
  62. 61.
    Sjögren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelsö C., et al. Both total and hyperphosphorylated tau are increased in Alzeimer’s disease. J. Neurol. Neurosurg. Psychiatry 70, 624–630.Google Scholar
  63. 62.
    Munroe W. A., Southwick P. C., Chang L., Scharre D. W., Echols C. L. Jr., Fu P. C., Whaley J. M., Wolfert R. L. (1995) Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. Ann. Clin. Lab. Sci. 25, 207–217.PubMedGoogle Scholar
  64. 63.
    Galasko D., Clark C., Chang L., Miller B., Green R. C., Motter R., Seubert P. (1997) Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 48, 632–635.PubMedGoogle Scholar
  65. 64.
    Galasko D., Chang L., Motter R., Clark C. M., Kaye J., Knopman D., et al. (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55, 937–945.PubMedCrossRefGoogle Scholar
  66. 65.
    Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., et al. (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 186, 181–183.PubMedCrossRefGoogle Scholar
  67. 66.
    Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., et al. (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 287, 187–190.PubMedCrossRefGoogle Scholar
  68. 67.
    Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van der Perre B., Sjögren M., et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49–52.PubMedCrossRefGoogle Scholar
  69. 68.
    Riemenschneider M., Schmolke M., Lautenschlager N., Guder W. G., Vanderstichele H., Vanmechelen E., and Kurz A. (2000) Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284, 85–88.PubMedCrossRefGoogle Scholar
  70. 69.
    Tamaoka A., Sawamura N., Fukushima T., Shoji S., Matsubara E., Shoji M., et al. (1997) Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Sci. 148, 41–45.PubMedCrossRefGoogle Scholar
  71. 70.
    Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., et al. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22,908–22,914.Google Scholar
  72. 71.
    Mehta P.D., Pirttilä T., Mehta S. P., Sersen E. A., Aisen P. S., and Wisniewski H. M. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57, 100–105.PubMedCrossRefGoogle Scholar
  73. 72.
    Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., and Blennow K. (1999c) CSF t-tau and CSF-Aβ42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neurosci. Lett. 273, 5–8.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  • Kaj Blennow
    • 1
    • 2
  • Eugeen Vanmechelen
    • 3
  • Harald Hampel
    • 4
  1. 1.Department of Clinical Neuroscience, Unit of NeurochemistryUniversity of GöteborgSweden
  2. 2.The Medical Research Council (MRC)Sweden
  3. 3.InnogeneticsGhentBelgium
  4. 4.Dementia and Neuroimaging Research Section and Memory Clinic, Department of PsychiatryLudwig-Maximilian UniversityMunichGermany
  5. 5.Dept. of Clinical Neuroscience, Unit of NeurochemistrySahlgren’s University HospitalMölndalSweden

Personalised recommendations